Entacapone improves complex movement performance in patients with Parkinson's disease

Area of Science:

• Neurology
• Pharmacology

Background:

• Parkinson's disease (PD) is characterized by impaired motor behavior.
• Levodopa/Carbidopa (LD/CD) is a standard treatment, but its plasma metabolism can be a limitation.
• Entacapone (EN) addition is explored to prolong LD/CD efficacy and improve motor symptoms.

Purpose of the Study:

• To evaluate the clinical response to increased dopaminergic substitution with EN.
• To assess the impact of EN on complex motor functions in PD patients.
• To investigate changes in movement patterns during repeat drug administration over an eight-hour interval.

Main Methods:

• A study involving 20 treated PD patients.
• Assessment of motor function using clinical rating and a computer-based peg insertion task.
• Standardized, open-label administration of LD/CD, followed by LD/CD plus EN.

Main Results:

• Significant improvements in motor scores were observed with LD/CD/EN.
• Enhanced performance in the instrumental peg insertion task.
• Reduced intensity of movement fluctuations during the LD/CD/EN condition.

Conclusions:

• Entacapone supplementation effectively improves motor symptoms in PD patients.
• EN contributes to more continuous and less fluctuating movement behavior.
• This combination therapy offers a potential strategy for better management of motor fluctuations in PD.